Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Angiodynamics Inc

NASDAQ: ANGO · Industrial Applications and Services · 3 alerts · CIK 1275187

Share price
$11.78Close, Nov 16
Market cap
$495M
Shares outstanding
42.05MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Angiodynamics Inc filings on SEC EDGAR ↗

4:15 PM ET Form 4
Insider Selling

Angiodynamics EVP and CFO Stephen A. Trowbridge Sells $311K of Stock

Stephen A. Trowbridge, EVP and CFO, sold 25,335 shares of Angiodynamics Inc at $12.17 to $12.27 a share (average $12.26) in 2 transactions, worth $311K in total between Oct 28, 2026 and Oct 29, 2026. Shares held after the trade: 280,461 (-7.8%).

Value
$311K
Shares
25,335
Average price
$12.26
Role
EVP and CFO
Holding change
-7.8%
Trade date
Oct 28, 2026 to Oct 29, 2026
7:18 AM ET 8-K
Financial Results

Angiodynamics Financial Results

AngioDynamics reported fiscal first quarter 2027 net sales of $80.9 million, representing 6.9% year-over-year growth driven by its Med Tech segment. The company achieved a GAAP gross margin of 59.4% and an adjusted EBITDA of $5.0 million. Additionally, the company announced that Eric Honroth will succeed Jim Clemmer as President and CEO effective November 2, 2026.

Term
Q1 2027

“Our first quarter results reflect the continued, consistent execution we’ve built into this business. Med Tech again led our growth, highlighted by Auryon’s 21st consecutive quarter of double-digit atherectomy growth, continued performance in Mechanical Thrombectomy, and ongoing strength in our NanoKnife oncology platform.”

Jim Clemmer, President and Chief Executive Officer

“As I shared previously, after ten years leading this company, I have decided to retire, and the Board has completed a comprehensive search for my successor. I’m pleased to share that Eric Honroth will become our next President and Chief Executive Officer.”

Jim Clemmer, President and Chief Executive Officer
7:17 AM ET 8-K
Executive Compensation

Angiodynamics Executive Compensation

AngioDynamics appointed Eric Honroth as President and Chief Executive Officer, effective November 2, 2026, succeeding the retiring James C. Clemmer. Honroth's employment agreement includes an annual base salary of $735,000, a target annual bonus of 95% of base salary, and eligibility for long-term incentive awards under the company's equity plan.

Counterparty
Eric Honroth
Term
1 year

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.